Coronavirus: Research Guidance for the ChristianaCare Community >

Advancing the Science and Precision of Gene Editing

ChristianaCare’s Gene Editing Institute is advancing the science of gene editing with one goal: accelerating cures for disease and improving treatments for all people through discovery, translational science and education. 

ChristianaCare’s Gene Editing Institute is a worldwide leader in CRISPR gene editing technology. Since launching in 2015 under the leadership and vision of gene editing pioneer Eric Kmiec, Ph.D., the Institute has grown rapidly, expanding its lab space and scientists tenfold. Today, the Institute is a wholly owned subsidiary of ChristianaCare and is spinning out a biotech company to commercialize its cancer therapy. International companies and organizations call upon the Institute for advice and partnerships and it has a vast grant portfolio which totals more than $3.5 million from the National Institutes of Health, National Science Foundation, Lisa Dean Moseley Foundation, The Wistar Institute, and New Castle County.